These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22943641)

  • 41. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
    Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
    Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
    Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
    Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
    Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
    Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.
    Smires FZ; Moreau C; Habbal R; Siguret V; Fadili S; Golmard JL; Assaidi A; Beaune P; Loriot MA; Nadifi S
    J Clin Pharm Ther; 2012 Oct; 37(5):594-8. PubMed ID: 22486182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
    Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
    J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
    Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
    Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.
    Michaud V; Vanier MC; Brouillette D; Roy D; Verret L; Noel N; Taillon I; O'Hara G; Gossard D; Champagne M; Goodman K; Renaud Y; Brown A; Phillips M; Ajami AM; Turgeon J
    Clin Pharmacol Ther; 2008 May; 83(5):740-8. PubMed ID: 18030307
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
    Schalekamp T; Brassé BP; Roijers JF; van Meegen E; van der Meer FJ; van Wijk EM; Egberts AC; de Boer A
    Clin Pharmacol Ther; 2007 Feb; 81(2):185-93. PubMed ID: 17192772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 53. CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with Factor V Leiden and prothrombin gene G2021A mutation(s).
    Leung A; Huang CK; Muto R; Liu Y; Pan Q
    Diagn Mol Pathol; 2007 Sep; 16(3):184-6. PubMed ID: 17721328
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Warfarin dosage response related pharmacogenetics in Chinese population.
    Li S; Zou Y; Wang X; Huang X; Sun Y; Wang Y; Dong L; Jiang H
    PLoS One; 2015; 10(1):e0116463. PubMed ID: 25594941
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of
    Li W; Zhao P; Chen L; Lai X; Shi G; Li L; Dong J
    Pharmacogenomics; 2020 Jan; 21(2):101-110. PubMed ID: 31854268
    [No Abstract]   [Full Text] [Related]  

  • 57. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.
    Hadjipanagi D; Chrysanthou S; Voskarides K; Deltas C
    BMC Res Notes; 2014 Mar; 7():123. PubMed ID: 24593903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.
    Helin TA; Joutsi-Korhonen L; Asmundela H; Niemi M; Orpana A; Lassila R
    Br J Clin Pharmacol; 2019 Aug; 85(8):1684-1691. PubMed ID: 30933373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes.
    Qazim B; Stöllberger C; Krugluger W; Dossenbach-Glaninger A; Finsterer J
    J Thromb Thrombolysis; 2009 Aug; 28(2):211-4. PubMed ID: 18629445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese.
    Tamura T; Katsuda N; Hamajima N
    Springerplus; 2014; 3():499. PubMed ID: 25932358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.